[1]华春波,陶宣辰,吕家誉,等.甲状腺癌组织miR-338、miR-143表达及其与患者临床病理特征和预后的关系[J].陕西医学杂志,2025,54(6):830-834.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.021]
　HUA Chunbo,TAO Xuanchen,LYU Jiayu,et al.Expression of miR-338 and miR-143 in thyroid cancer tissues and their relationship with clinicopathologic features and prognosis[J].,2025,54(6):830-834.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.021]
点击复制

甲状腺癌组织miR-338、miR-143表达及其与患者临床病理特征和预后的关系

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年6期
页码:
830-834
栏目:
临床病理
出版日期:
2025-06-05

文章信息/Info

Title:
Expression of miR-338 and miR-143 in thyroid cancer tissues and their relationship with clinicopathologic features and prognosis
作者:
华春波1; 陶宣辰2; 吕家誉1; 王宇1
（1.哈尔滨市第五医院普外科，黑龙江 哈尔滨 150040；2.哈尔滨医科大学附属第二医院普外科，黑龙江 哈尔滨 150040）
Author(s):
HUA Chunbo1; TAO Xuanchen2; LYU Jiayu1; WANG Yu1
(1.Department of General Surgery,the Fifth Hospital of Harbin City,Harbin 150040,China;2.Department of General Surgery,the Second Affiliated Hospital of Harbin Medical University,Harbin 150040,China)
关键词:
甲状腺癌; 微小RNA-338; 微小RNA-143; 临床病理特征; 预后; 生存曲线
Keywords:
Thyroid cancer; miR-338; miR-143; Clinicopathologic feature; Prognosis; Survival curve
分类号:
R 736.1
DOI:
DOI:10.3969/j.issn.1000-7377.2025.06.021
文献标志码:
A
摘要:
目的：探讨甲状腺癌（TC）组织微小RNA（miR）-338、miR-143表达及其与患者临床病理特征和预后的关系。方法：收集120例TC患者病历资料、TC组织及癌旁组织（距肿瘤边缘＞5 cm），将TC组织、癌旁组织分别记为TC组和癌旁组。实时荧光定量PCR（RT-qPCR）法测定TC组织及癌旁组织miR-338、miR-143表达水平。分析miR-338、miR-143表达水平与TC患者临床病理特征的关系。Kaplan-Meier法绘制TC患者生存曲线，Cox回归分析TC患者预后的影响因素。结果：与癌旁组比较，TC组miR-338、miR-143表达水平显著降低（均P＜0.05）。肿瘤最大径>2 cm、发生淋巴结转移、包膜侵犯及低分化程度TC患者miR-338和miR-143表达水平低于肿瘤最大径≤2 cm、淋巴结未转移、未包膜侵犯及高中分化程度患者（均P＜0.05）。miR-338、miR-143高表达患者中，术后5年生存率显著高于低表达患者（均P＜0.05）。Cox回归分析结果显示，肿瘤最大径、淋巴结转移、分化程度、miR-338、miR-143表达是TC患者预后不良的影响因素（均P＜0.05）。结论：TC组织miR-338、miR-143表达水平均显著低于癌旁组织，且两者表达水平与TC患者临床病理特征及预后密切相关。
Abstract:
Objective:To explore the expression of miR-338 and miR-143 in thyroid cancer (TC) tissues and their relationship with clinicopathologic features and prognosis.Methods：Medical records,TC tissues and adjacent cancer tissues (>5 cm from the tumor edge) were collected from 120 TC patients,and TC tissues and adjacent cancer tissues were recorded as TC group and adjacent cancer group,respectively.RT-qPCR was applied to determine the expression levels of miR-338 and miR-143 in TC tissues and adjacent cancer tissues.The relationship between the expression levels of miR-338 and miR-143 with the clinicopathologic features of TC patients was analyzed.Kaplan-Meier method was applied to plot the survival curve.Cox regression was applied to analyze the influencing factors of prognosis in TC patients.Results:Compared with the adjacent cancer group,the expression levels of miR-338 and miR-143 in the TC group were obviously lower (all P<0.05).The expression levels of miR-338 and miR-143 in TC patients with maximum tumor diameter >2 cm,lymph node metastasis,capsule invasion,and low differentiation were lower than those in TC patients with maximum tumor diameter ≤2 cm,no lymphnode metastasis,no capsule invasion,and high differentiation (all P<0.05).The 5-year postoperative survival rates of patients with high expressions of miR-338 and miR-143 were obviously higher than those of patients with low expression of miR-338 and miR-143 (all P＜0.05).Cox regression analysis results showed that the maximum tumor diameter,lymph node metastasis,degree of differentiation,and expressions of miR-338 and miR-143 were all factors affecting the poor prognosis of TC patients (all P<0.05).Conclusion:The expression levels of miR-338 and miR-143 in TC tissues are obviously lower than those in adjacent tissues,and their expression levels are closely related to clinicopathologic features and prognosis of TC patients.

参考文献/References:

[1]MIRANDA-FILHO A,LORTET-TIEULENT J,BRAY F,et al.Thyroid cancer incidence trends by histology in 25 countries：A population-based study[J].Lancet Diabetes Endocrinol,2021,9(4)：225-234.
[2]王媛媛,朱静,刘娜娜,等.溶质载体家族1成员5及谷氨酰胺酶2对人甲状腺癌细胞体外恶性行为的影响及机制研究[J].陕西医学杂志,2023,52(3)：344-348.
[3]傅强,黄学阳,王建春,等.养阴散结汤辅助治疗分化型甲状腺癌疗效及对患者术后甲状腺、免疫功能和血清学指标的影响[J].陕西中医,2022,43(8)：1029-1031,1036.
[4]李卫,王猛,刘杰.甲状腺乳头状癌组织miR-144-5p、FN1表达变化及其与临床病理特征和预后的关系[J].山东医药,2022,62(25)：25-29.
[5]张燕妮,胡玉海.血清VAP-1、VCAM-1在甲状腺癌患者中的变化及意义[J].检验医学与临床,2023,20(18)：2715-2719.
[6]ZHANG R,LIU P,ZHANG X,et al.Lin28A promotes the proliferation and stemness of lung cancer cells via the activation of mitogen-activated protein kinase pathway dependent on microRNA let-7c[J].Ann Transl Med,2021,9(12)：982-1001.
[7]王威,邓瑞,周培华.南蛇藤提取物通过调控微小RNA-378对结肠癌细胞生物学行为的影响[J].河北中医,2024,46(12)：2017-2023.
[8]HE W,LU J.MiR-338 regulates NFATc1 expression and inhibits the proliferation and epithelial-mesenchymal transition of human non-small-cell lung cancer cells[J].Mol Genet Genomic Med,2020,8(2)：e1091-e1100.
[9]杨新选,任航.膀胱癌患者血清miR-143、miR-144和miR-145水平变化及临床意义[J].海南医学,2021,32(21)：2725-2729.
[10]HONG S,XIE Y,CHENG Z,et al.Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability[J].Oncogene,2022,41(47)：5121-5132.
[11]王树庚.健脾益气汤联合化疗治疗甲状腺癌及对患者免疫功能的影响[J].陕西中医,2016,37(10)：1372-1373.
[12]王思寅,董颖,滕立勤.甲状腺癌组织中miR-93-5p、BRMS1L的表达水平及其临床意义[J].实用癌症杂志,2023,38(4)：538-541.
[13]赵莉娅,赵铁铮,庞英,等.乐伐替尼对甲状腺癌SW579细胞放射敏感性及血管内皮生长因子、碱性成纤维细胞生长因子、碱性成纤维细胞生长因子受体表达的影响[J].陕西医学杂志,2023,52(8)：956-959.
[14]陈肖玥,孙健雯,张国强,等.免疫检查点IDO-1、LAG-3、TIM-3与分化型甲状腺癌临床病理特征及预后的相关性[J].中华核医学与分子影像杂志,2021,41(4)：196-200.
[15]张莉,王亮,王俊,等.甲状腺癌组织中DGCR8与DICER1基因表达及临床意义[J].疑难病杂志,2022,21(8)：840-844.
[16]BOLAYIRLI I M,NAL B,ADIGUZEL M,et al.The clinical significance of circulating miR-21,miR-142,miR-143,and miR-146a in patients with prostate cancer[J].J Med Biochem,2022,41(2)：191-198.
[17]闫柄文,张仔昂,薛萍.miR-16-5p通过靶向SPARC促进人瘢痕疙瘩成纤维细胞凋亡的研究[J].空军军医大学学报,2023,44(7)：655-660.
[18]沈美琴,施颖琦,陆飞,等.胃癌组织中miR-143-3p、LASP1表达与临床病理特征和预后的关系[J].山东医药,2022,62(34)：16-20.
[19]罗利花,霍翠敏,耿欣,等.子宫内膜癌患者miR-338-3p、PTEN、CA125表达与病理特征相关性[J].中国优生与遗传杂志,2023,31(7)：1426-1431.
[20]CHANG J,LIU S,LI B,et al.MiR-338-3p improved lung adenocarcinoma by AKAP12 suppression[J].Arch Med Sci,2019,17(2)：462-473.
[21]罗婵娟.子宫内膜癌组织中miR-143的表达及与预后的相关性分析[J].医学信息,2022,35(15)：75-78.
[22]SUN J,CHEN L,DONG M.MiR-338-5p inhibits EGF-induced EMT in pancreatic cancer cells by targeting EGFR/ERK signaling[J].Front Oncol,2021,11(2)：616481-616491.
[23]CHU C A,LEE C T,LEE J C,et al.MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase,catalytic subunit type 3-mediated autophagy pathway[J].EBioMedicine,2019,43：270-281.
[24]王丽丽,崔艳歆,崔华硕.外周血miR-143、miR-33a水平与膀胱癌临床病理特征及化疗疗效的关系[J].分子诊断与治疗杂志,2022,14(6)：966-969,974.
[25]李秀明,刘璐,万琼,等.新辅助治疗后血清miR-448和miR-143水平对胰腺癌患者术后生存和预后的影响[J].实用癌症杂志,2022,37(8)：1331-1334.
[26]宗振峰,唐国杰,国玉.miR-338-3p靶向MACC1调节MEK/ERK信号通路抑制非小细胞肺癌的增殖和EMT[J].临床肺科杂志,2022,27(11)：1723-1728.
[27]韩琳,曾群章.miR-143靶向TREM1调控免疫因子白介素-6/10对克罗恩病模型肠黏膜HT-29细胞增殖的影响机制[J].免疫学杂志,2023,39(3)：216-224.
[28]LI M,LIU Y,LIU J,et al.Circ_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143[J].Aging (Albany NY),2019,11(22)：10626-10643.

相似文献/References:

[1]陈宏月,李兴江△.甲状腺全切除术对甲状腺癌患者血清血管内皮生长因子、可溶性Fas受体、可溶性Fas受体配体mRNA表达的影响研究[J].陕西医学杂志,2020,49(1):96.
　CHEN Hongyue,LI Xingjiang..Effect of total thyroidectomy on mRNA expression levels of VEGF,sFas and sFasL in serum of patients with thyroid cancer[J].,2020,49(6):96.
[2]谢新静,李忠原.实时剪切波弹性成像联合甲状腺球蛋白抗体检测在甲状腺癌诊断中的应用研究[J].陕西医学杂志,2021,50(2):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
　XIE Xinjing,LI Zhongyuan.Application of real-time shear wave elastography combined with Tg-Ab detection in diagnosis of thyroid cancer[J].,2021,50(6):154.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.007]
[3]林松荣,张 磊,罗金现,等.DNA甲基化修饰在甲状腺癌中的研究进展[J].陕西医学杂志,2021,50(2):254.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
　LIN Songrong,ZHANG Lei,LUO Jinxian,et al.Research progress of DNA methylation in thyroid cancer[J].,2021,50(6):254.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.033]
[4]石维超,张少波.甲状腺癌病理微血管密度与颈部淋巴结转移相关性研究[J].陕西医学杂志,2022,51(11):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]
　SHI Weichao,ZHANG Shaobo.Correlation between pathological microvessel density and cervical lymph node metastasis in thyroid cancer[J].,2022,51(6):1449.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.031]
[5]王媛媛,朱 静,刘娜娜,等.溶质载体家族1成员5及谷氨酰胺酶2对人甲状腺癌细胞体外恶性行为的影响及机制研究[J].陕西医学杂志,2023,52(3):344.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.023]
　WANG Yuanyuan,ZHU Jing,LIU Nana,et al.Effect of solute carrier family 1 member 5 and glutaminases 2 on malignant behavior of human thyroid cancer cells in vitro and its mechanism[J].,2023,52(6):344.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.023]
[6]宋传伟,刘兆芳,刘兆琳.血清Tg、TgAb、ZEB1水平对甲状腺癌术后清甲治疗患者疾病复发的预测价值[J].陕西医学杂志,2025,54(6):825.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.020]
　SONG Chuanwei,LIU Zhaofang,LIU Zhaolin.Predictive value of Tg,TgAb and ZEB1 levels for recurrence of thyroid cancer in patients with thyroid remnant ablation after thyroidectomy[J].,2025,54(6):825.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.020]

备注/Memo

备注/Memo:
黑龙江省医药卫生科研课题（20230404070350）
更新日期/Last Update: 2025-06-04